コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 r loss or dysfunction is implicated in human neuropsychiatric disease.
2 olding protein that has been associated with neuropsychiatric disease.
3 vitro studies informing novel therapies in a neuropsychiatric disease.
4 herapeutic interest in neurodegeneration and neuropsychiatric disease.
5 at the core of disturbed social behavior in neuropsychiatric disease.
6 and susceptibility to neurodegenerative and neuropsychiatric disease.
7 ay a role in synaptic dysfunction underlying neuropsychiatric disease.
8 ycles and synaptic dysfunction in a model of neuropsychiatric disease.
9 emerged as a potential therapeutic target in neuropsychiatric disease.
10 tion may contribute to behaviors observed in neuropsychiatric disease.
11 in the study of circuit function relevant to neuropsychiatric disease.
12 ge at the level of the glia to contribute to neuropsychiatric disease.
13 in both normal animals and animal models of neuropsychiatric disease.
14 nderstanding human physiology, behavior, and neuropsychiatric disease.
15 model might be more generally applicable to neuropsychiatric disease.
16 ensive care unit (ICU)-acquired weakness and neuropsychiatric disease.
17 rve as a useful biomarker in mouse models of neuropsychiatric disease.
18 obiologic systems that are often abnormal in neuropsychiatric disease.
19 sive topic of study despite its relevance to neuropsychiatric disease.
20 discussed with regard to a monkey model for neuropsychiatric disease.
21 egies of study and therapeutics in childhood neuropsychiatric disease.
22 lt offspring brain, mimicking those in human neuropsychiatric disease.
23 [123I]beta-CIT in serial evaluation of human neuropsychiatric disease.
24 al quantitative variation and in relation to neuropsychiatric disease.
25 anifestation of a broader pattern of chronic neuropsychiatric disease.
26 e functional relevance of such regulation to neuropsychiatric disease.
27 tation-transcription coupling both relate to neuropsychiatric disease.
28 ological basis of reward- and stress-related neuropsychiatric disease.
29 for future translational relevance to human neuropsychiatric disease.
30 nd subcortical regions associated with human neuropsychiatric disease.
31 s associated with neurological disorders and neuropsychiatric disease.
32 ess that can become compromised in aging and neuropsychiatric disease.
33 subtle molecular changes that contribute to neuropsychiatric disease.
34 ibutions to fear and anxiety and its role in neuropsychiatric disease.
35 s could lead to cognitive control failure in neuropsychiatric disease.
36 human brain organoids as in vitro models of neuropsychiatric disease.
37 all fluctuations in protein quantity lead to neuropsychiatric disease.
38 lar events that, when disrupted, can lead to neuropsychiatric disease.
39 n for aggression arising in certain forms of neuropsychiatric disease.
40 al care, such as evaluation for metabolic or neuropsychiatric disease.
41 nosology of biomarkers used in the study of neuropsychiatric disease.
42 processes disrupted in neurodegenerative and neuropsychiatric disease.
43 transcriptional mechanisms that may underlie neuropsychiatric disease.
44 upporting the utility of phNPCs for studying neuropsychiatric disease.
45 ng how researchers conceptualize and explore neuropsychiatric disease.
46 utilization, highlighting their relevance to neuropsychiatric disease.
47 indles may represent heritable biomarkers of neuropsychiatric disease.
48 isk and (potentially) protective factors for neuropsychiatric disease.
49 ng in the evaluation of somatic mutations in neuropsychiatric disease.
50 could have applicability to other studies in neuropsychiatric disease.
51 ements established gene-mapping paradigms in neuropsychiatric disease.
52 ls provide a powerful opportunity to examine neuropsychiatric diseases.
53 d patients with specific treatment-resistant neuropsychiatric diseases.
54 s in understanding and treating a variety of neuropsychiatric diseases.
55 ognitive processing and disrupted in diverse neuropsychiatric diseases.
56 h is critical for studying disorders such as neuropsychiatric diseases.
57 etween ASDs and other neurodevelopmental and neuropsychiatric diseases.
58 in these processes that are observed in many neuropsychiatric diseases.
59 ous associations with developmental delay or neuropsychiatric diseases.
60 ssociated with certain neurodegenerative and neuropsychiatric diseases.
61 to be upregulated in patients suffering from neuropsychiatric diseases.
62 lligence measures and capacity is reduced in neuropsychiatric diseases.
63 l thickness as an intermediate phenotype for neuropsychiatric diseases.
64 to risk for bipolar disorder and other major neuropsychiatric diseases.
65 Stress is a major risk factor for numerous neuropsychiatric diseases.
66 also credited as a major player in a host of neuropsychiatric diseases.
67 omplex brain related traits, including human neuropsychiatric diseases.
68 ciated with a wide range of neurological and neuropsychiatric diseases.
69 ion-deficit hyperactivity disorder and other neuropsychiatric diseases.
70 ique for a variety of movement disorders and neuropsychiatric diseases.
71 lex behaviors and might be perturbed in some neuropsychiatric diseases.
72 served associations between DAT genotype and neuropsychiatric diseases.
73 ws into the pathophysiology and treatment of neuropsychiatric diseases.
74 an important concept in the study of complex neuropsychiatric diseases.
75 r, neuronal development, and the sequella of neuropsychiatric diseases.
76 ealing mitochondrial defects associated with neuropsychiatric diseases.
77 ruption of this function may underlie severe neuropsychiatric diseases.
78 matic and neuroprotective therapy of various neuropsychiatric diseases.
79 considered as candidates for diabetes and/or neuropsychiatric diseases.
80 mimetics for the potential treatment of the neuropsychiatric diseases.
81 d framework for future analyses of miRNAs in neuropsychiatric diseases.
82 an emerging therapy for diverse, refractory neuropsychiatric diseases.
83 thogenesis of a wide range of neurologic and neuropsychiatric diseases.
84 aviors could become targets for treatment of neuropsychiatric diseases.
85 raits (pleiotropy), including autoimmune and neuropsychiatric diseases.
86 related phenotypes, including cognition and neuropsychiatric diseases.
87 we demonstrate clinical use of the model in neuropsychiatric diseases.
88 rol of chronic infectious, inflammatory, and neuropsychiatric diseases.
89 known to cognitive neuroscience and in most neuropsychiatric diseases.
90 ting abilities, are core features of several neuropsychiatric diseases.
91 rged as a promising therapeutic strategy for neuropsychiatric diseases.
92 erapeutic target for sleep disorders and for neuropsychiatric diseases accompanied by weakened sleep
94 s consistent associations between a specific neuropsychiatric disease and a particular environmental
97 his study, we report eleven individuals with neuropsychiatric disease and copy-number variations span
98 s how these data inform our understanding of neuropsychiatric disease and discuss the potential role
99 g underlying mechanisms and implications for neuropsychiatric disease and new treatment approaches.
100 ches to optimization of stimulation for each neuropsychiatric disease and we review the potential pos
102 and social deficits lie at the core of many neuropsychiatric diseases and are among the many behavio
104 ctory and other sensory maps, as well as for neuropsychiatric diseases and traits modulated by the BD
105 t opportunity of understanding complex human neuropsychiatric disease), and no work has characterized
106 e death, 14 elderly control patients with no neuropsychiatric disease, and 10 control patients with A
107 el candidate for intellectual disability and neuropsychiatric disease, and elucidate a mechanism of p
108 , urinary incontinence, gastrointestinal and neuropsychiatric diseases, and skeletal muscle disorders
111 mber of human clinical phenotypes, including neuropsychiatric diseases associated with dysregulation
112 ontal 5-HT1A receptors with implications for neuropsychiatric diseases associated with emotional dysf
113 erstanding of the regulome and the impact of neuropsychiatric disease-associated genetic risk variant
114 echanistic insight to the processes by which neuropsychiatric diseases at a young age affect the risk
115 ovide strong evidence that familial risk for neuropsychiatric disease becomes more relevant to ASD et
117 e implicated in cognitive impairment in many neuropsychiatric diseases, but acetylcholine's specific
118 substrates of choice, with implications for neuropsychiatric diseases characterized by dopaminergic
119 overy of new syndromes and genes involved in neuropsychiatric disease despite extensive genetic heter
120 hizophrenia and the control patients without neuropsychiatric disease for the densities of any of the
122 we are likely transitioning into a phase of neuropsychiatric disease genetics in which the rate-limi
123 rare and de novo mutations, is transforming neuropsychiatric disease genetics through identifying on
128 Drug addiction and neurodegenerative and neuropsychiatric diseases have all been associated with
130 Alcoholism is one of the most prevalent neuropsychiatric diseases, having an enormous health and
131 erspective toward understanding and treating neuropsychiatric disease, highlighting the therapeutic p
132 eminal contributions to the understanding of neuropsychiatric disease; his works substantially added
133 come and Measures: The prevalence of defined neuropsychiatric disease in first-degree and second-degr
134 ) and the liver (P = 0.003), and 14 SNPs for neuropsychiatric disease in neuronal tissues (P = 0.007)
136 creased aggregation of neurodegenerative and neuropsychiatric disease in the context of the recently
139 udies reported a decreased number of VENs in neuropsychiatric diseases in which the "embodied" dimens
141 aspartate receptors (NMDARs) to a variety of neuropsychiatric diseases including alcoholism, but deve
142 ilation are important features of a range of neuropsychiatric diseases including obsessive compulsive
144 contribute to the propensity for developing neuropsychiatric disease, including substance abuse diso
145 bilitating clinical feature of many forms of neuropsychiatric disease, including Tourette syndrome, o
146 ures related to either neuronal processes or neuropsychiatric diseases, including a human-specific mo
147 lopment of new therapeutics for treatment of neuropsychiatric diseases, including alcohol use disorde
149 gnition, and one that is impaired in several neuropsychiatric diseases, including attention deficit/h
150 and glia have been evaluated as mediators of neuropsychiatric diseases, including drug addiction.
151 unctions are a common denominator in several neuropsychiatric diseases, including DS, but the contrib
152 enesis or exploited in the treatment of many neuropsychiatric diseases, including Parkinson's disease
153 symmetry breaking is associated with several neuropsychiatric diseases, including schizophrenia and a
154 cortical interneurons has been implicated in neuropsychiatric diseases, including schizophrenia, auti
155 er understand the mechanisms associated with neuropsychiatric diseases, including schizophrenia.
157 cated in various developmental processes and neuropsychiatric diseases, its role in neurodevelopment
158 ht indicate that findings in mouse models of neuropsychiatric diseases may not be directly transferre
159 of a genomics-driven approach to uncovering neuropsychiatric disease mechanisms and facilitating the
162 cerebrospinal fluid from patients with three neuropsychiatric diseases of childhood for the presence
163 molecular techniques to the understanding of neuropsychiatric disease, outlining the potential of zeb
164 able challenge to the study and treatment of neuropsychiatric diseases, owing to the complex interact
165 rogenesis, which is impaired in DS and other neuropsychiatric diseases, plays a key role in hippocamp
166 al stimuli and is also implicated in diverse neuropsychiatric diseases, provides a less ambiguous mea
168 ding of the molecular and cellular causes of neuropsychiatric disease remains limited, which leads to
169 nges are associated with increased offspring neuropsychiatric disease risk, and likely contribute to
172 including non-sectioned human tissue from a neuropsychiatric-disease setting, establishing a path fo
173 regulation is the most common feature across neuropsychiatric diseases, sex differences in how these
174 ases, including allergies and autoimmune and neuropsychiatric diseases, share common pathways of cell
175 number variants (CNVs) play a role in other neuropsychiatric diseases, so we assessed their associat
178 es have identified rare CNVs associated with neuropsychiatric diseases such as autism, schizophrenia,
180 ities of PUFA status have been implicated in neuropsychiatric diseases such as major depression, bipo
181 essential to developing novel therapies for neuropsychiatric diseases such as OCD and ASDs with Hoxb
182 eaves neuropeptides and is a drug target for neuropsychiatric diseases such as post-traumatic stress
183 f behavioral control as observed in aging or neuropsychiatric diseases such as schizophrenia and addi
184 as Alzheimer's and Parkinson's disease, and neuropsychiatric diseases, such as autism and schizophre
187 searchers in an approach to the diagnosis of neuropsychiatric disease that is inclusive and comprehen
188 There is an overlap between ALS, FTD, and neuropsychiatric disease that is pronounced in kindreds
189 of biomedical data provides a perspective on neuropsychiatric disease that may be otherwise elusive.
190 hese findings could provide new insight into neuropsychiatric diseases that involve improper generali
191 abnormal kidney and muscle development, and neuropsychiatric disease, this Fat1 function may have im
192 morphological cerebral aberrations found in neuropsychiatric disease through exact neuropathological
193 ion medicine that better guide patients with neuropsychiatric diseases to optimal available treatment
194 ated conditions are among the most difficult neuropsychiatric diseases to treat pharmacologically, bu
195 acknowledged, including concomitant or past neuropsychiatric disease, use of corticosteroids, diseas
196 amily members of other neurodegenerative and neuropsychiatric disease was calculated using the relati
197 Given the possible involvement of Ih in neuropsychiatric diseases, we have also characterized Ih
198 ment and also in studies of neurological and neuropsychiatric diseases where disruptions of normal gl
199 particular interest as a candidate gene for neuropsychiatric diseases with a developmental etiology,
201 their impact on vulnerability to drug abuse, neuropsychiatric diseases with differential expression a
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。